Merck KGaA
XETRA:MRK
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (17.2), the stock would be worth €146.32 (31% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 13.2 | €111.9 |
0%
|
| 3-Year Average | 17.2 | €146.32 |
+31%
|
| 5-Year Average | 18.3 | €155.72 |
+39%
|
| Industry Average | 18.4 | €155.94 |
+39%
|
| Country Average | 15.5 | €132.09 |
+18%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€54.3B
|
/ |
Jan 2026
€4.3B
|
= |
|
|
€54.3B
|
/ |
Dec 2026
€4.2B
|
= |
|
|
€54.3B
|
/ |
Dec 2027
€4.7B
|
= |
|
|
€54.3B
|
/ |
Dec 2028
€5B
|
= |
|
|
€54.3B
|
/ |
Dec 2029
€5.1B
|
= |
|
|
€54.3B
|
/ |
Dec 2030
€5.5B
|
= |
|
|
€54.3B
|
/ |
Dec 2031
€5.8B
|
= |
|
|
€54.3B
|
/ |
Dec 2032
€6.1B
|
= |
|
|
€54.3B
|
/ |
Dec 2033
€6.2B
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| DE |
|
Merck KGaA
XETRA:MRK
|
48.7B EUR | 13.2 | 18.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 29.2 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 21.4 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 21.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 15.6 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 11.5 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.8 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 10.1 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 8.9 | 16.8 |
Market Distribution
| Min | 0.1 |
| 30th Percentile | 10.6 |
| Median | 15.5 |
| 70th Percentile | 23.1 |
| Max | 672.9 |
Other Multiples
Merck KGaA
Glance View
In the heart of Darmstadt, Germany, Merck KGaA stands as a testament to innovation and resilience, tracing its roots back to 1668. A bastion of scientific advancement and a pioneer in the world of chemistry and pharmaceuticals, Merck has evolved through centuries of discovery and transformation. Originally a humble pharmacy, Merck has grown into a global powerhouse with a unique structure, being one of the oldest pharmaceutical and chemical companies in the world still owned by the founding family. Though its path has been influenced by numerous historical events, Merck has adeptly navigated the shifting sands of time, transforming itself into a multifaceted conglomerate that thrives on its dual strategy—life sciences and performance materials. In the modern age, Merck KGaA operates through three well-defined sectors: Healthcare, Life Science, and Electronics. Its Healthcare division plays a formidable role, developing innovative drugs, with a focus on oncology, neurology, and immunology, providing cutting-edge treatments that improve patient lives globally. Meanwhile, the Life Science arm caters to researchers and scientists, offering an extensive portfolio of lab materials, high-tech tools, and equipment essential for groundbreaking research across various industries. The Electronics division, dedicated to performance materials, supplies high-quality substances crucial for the electronics and automotive industries, including liquid crystals and highly sophisticated semiconductor solutions. Through these divisions, Merck KGaA not only generates substantial revenue but also drives progress by supplying critical products that are indispensable to the modern technological landscape.
